|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
66,230,000 |
Market
Cap: |
4.11(M) |
Last
Volume: |
362,100 |
Avg
Vol: |
358,710 |
52
Week Range: |
$0.062 - $0.062 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Petit Robert |
Chief Scientific Officer |
|
2017-04-28 |
4 |
A |
$8.56 |
$2,140 |
D/D |
250 |
119,847 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-04-28 |
4 |
A |
$8.56 |
$2,987 |
D/D |
349 |
297,091 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-04-28 |
4 |
A |
$8.56 |
$1,584 |
D/D |
185 |
127,456 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-03-31 |
4 |
A |
$8.17 |
$2,982 |
D/D |
365 |
296,742 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-03-31 |
4 |
S |
$8.24 |
$20,221 |
D/D |
(2,454) |
119,597 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-03-31 |
4 |
A |
$8.17 |
$1,789 |
D/D |
219 |
122,051 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-03-31 |
4 |
A |
$8.17 |
$1,585 |
D/D |
194 |
127,271 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-02-28 |
4 |
D |
$8.79 |
$914 |
D/D |
(104) |
296,377 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-02-28 |
4 |
A |
$8.79 |
$4,307 |
D/D |
490 |
296,481 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-02-28 |
4 |
D |
$8.79 |
$536 |
D/D |
(61) |
127,077 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-02-28 |
4 |
A |
$8.79 |
$2,312 |
D/D |
263 |
127,138 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-02-28 |
4 |
D |
$8.79 |
$457 |
D/D |
(52) |
121,832 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-02-28 |
4 |
A |
$8.79 |
$2,619 |
D/D |
298 |
121,884 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-01-31 |
4 |
D |
$8.96 |
$502 |
D/D |
(56) |
126,875 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2017-01-31 |
4 |
A |
$8.96 |
$2,240 |
D/D |
250 |
126,931 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-01-31 |
4 |
D |
$8.96 |
$869 |
D/D |
(97) |
295,991 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2017-01-31 |
4 |
A |
$8.96 |
$4,175 |
D/D |
466 |
296,088 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-01-31 |
4 |
D |
$8.96 |
$430 |
D/D |
(48) |
121,586 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2017-01-31 |
4 |
A |
$8.96 |
$2,527 |
D/D |
282 |
121,634 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-12-30 |
4 |
D |
$7.16 |
$1,353 |
D/D |
(189) |
126,681 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-12-30 |
4 |
A |
$0.00 |
$3,057 |
D/D |
50,427 |
126,870 |
|
- |
|
Bonstein Sara |
Chief Financial Officer |
|
2016-12-30 |
4 |
S |
$7.37 |
$40,682 |
D/D |
(5,520) |
126,443 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-12-30 |
4 |
D |
$7.16 |
$666 |
D/D |
(93) |
121,352 |
|
- |
|
Petit Robert |
Chief Scientific Officer |
|
2016-12-30 |
4 |
A |
$7.16 |
$3,408 |
D/D |
476 |
121,445 |
|
- |
|
O'connor Daniel |
Chief Executive Officer |
|
2016-12-30 |
4 |
D |
$7.16 |
$1,375 |
D/D |
(192) |
295,622 |
|
- |
|
454 Records found
|
|
Page 4 of 19 |
|
|